Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial

Lancet

Volumn 364, Issue 9435, 2004, Pages 665-674

  Schnitzer, Thomas J ^a   Burmester, Gerd R ^b   Mysler, Eduardo ^c   Hochberg, Marc C ^d   Doherty, Michael ^e   Ehrsam, Elena ^f   Gitton, Xavier ^f   Krammer, Gerhard ^f   Mellein, Bernhard ^f   Matchaba, Patrice ^f   Gimona, Alberto ^f   Hawkey, Christopher J ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Org Médica de Investigation ^*  (Argentina)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; DICLOFENAC; DRUG DERIVATIVE; ORGANIC COMPOUND; PROSTAGLANDIN SYNTHASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGE; AGED; ANEMIA; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG USE; DYSPEPSIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HELICOBACTER INFECTION; HEMATEMESIS; HEMATOCHEZIA; HUMAN; INCIDENCE; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STOMACH OBSTRUCTION; STROKE; STUDY; TOXIC HEPATITIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MIDDLE AGED; OSTEOARTHRITIS; PEPTIC ULCER BLEEDING; ULCER PERFORATION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; NAPROXEN; ORGANIC CHEMICALS; OSTEOARTHRITIS; PEPTIC ULCER HEMORRHAGE; PEPTIC ULCER PERFORATION;

EID: 4344661128     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16893-1     Document Type: Article

References (47)

1. American College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 43:2000;1905-1915
2. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis - report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 62:2003;1145-1155
3. Hochberg MC. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin Arthritis Rheum. 32:(3 supp1):2002;4-14
4. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 340:1999;1888-1899
5. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 120:2001;594-606
6. Fries JF. NSAID gastrophathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol. 18:(suppl 26):1991;6-10
7. Hawkey CJ, Langman MJS. Non-steroidal anti-inflammatory drugs: overall risks and management - complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut. 52:2003;600-608
8. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 345:2001;433-442
9. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study - a randomized controlled trial. JAMA. 284:2000;1247-1255
10. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528
11. Laine L. Gastrointestinal safety of coxibs and outcomes studies: what's the verdict? J Pain Symptom Manage. 23:(suppl 4):2002;S5-10
12. US Food and Drug Administration. Statistical Reviewer Briefing Document for the Advisory Committee.http://www.fda.gov/ ohrms/dockets/ac/01/briefing/ 3677b1_04_stats.doc (accessed May 12, 2004).
13. Merck. Vioxx (rofecoxib tablets and oral suspension) prescribing information. March, 2004. Available from:http://www.vioxx.com/vioxx/shared/ documents/english/pi.pdf (accessed May 12, 2004).
14. Fitzgerald GA. COX-2 and beyond: approaches to prostagland in inhibition in human disease. Nat Rev Drug Discov. 2:2003;879-890
15. Marshall PJ, Berry JC, Wasvary J, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2. Ann Rheum Dis 2002; 61 (suppl 1): 259 (abstr SAT0013).
16. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos. 32:2004;566-571
17. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol. 33:2004;1-6
18. Scott G, Rordorf C, Blood P, Branson J, Milosavljev S, Greig G. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann Rheum Dis 2002; 61 (suppl 1): 242 (abstr FRI0300).
19. Benevolenskaya L, Tüzün S, Hagin E, Moore A, Gimona A. Lumiracoxib is effective in relieving symptoms of knee or hip osteoarthritis after 4 weeks of treatment: results from a randomized, placebo-controlled trial. Ann Rheum Dis 2003; 62 (suppl 1): 270 (abstr FRI0246).
20. Tannenbaum H, Berenbaum F, Reginster J-Y, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis; published online Feb 27, 2004. DOI 10.1136/ard.2003.015974 (accessed July 28, 2004)
21. Rordorf C, Kellett N, Mair S, et al. Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther. 18:2003;533-541
22. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther. 19:2004;1189-1198
23. Hawkey CJ, Svoboda P, Fiedorowicz-Fabrycy IF, et al. Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J Rheum (in press).
24. Hawkey CJ, Farkouh M, Gitton X, Ehrsam E, Huels J, Richardson P. Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib: study design and patient demographics. Aliment Pharmacol Ther. 20:2004;51-63
25. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum. 29:1986;1039-1049
26. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 33:1990;1601-1610
27. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 34:1991;505-514
28. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. J Am Coll Cardiol. 34:1999;1348-1359
29. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
30. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 364:2004;675-684
31. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 1980;John Wiley and Sons, New York
32. Cox RD. Regression models and life-tables (with Discussion). J Royal Stat Soc. 34:1972;187-220
33. Pham T, Van Der Heijde D, Lassere M, et al. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J Rheumatol. 30:2003;1648-1654
34. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Int Med. 115:1991;787-796
35. Hawkey C, Hoexter G, Richard D, Gitton X, Weinstein W. Lumiracoxib, a novel cyclooxygenase-2 selective inhibitor, has improved gastrointestinal safety and tolerability compared with nonselective nonsteroidal anti-inflammatory drugs: a pooled analysis. Arthritis Rheum 2003; 48 (suppl 9): 79 (abstr 87).
36. Hochberg MC. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Clin Exp Rheumatol. 19:(suppl 25):2001;S15-22
37. Hawkey CJ. NSAIDs and COX-2 inhibitors: what can we learn from large outcome trials? The gastroenterologist's perspective. Clin Exp Rheumatol. 19:(suppl 25):2001;S23-30
38. Juni P. Are selective COX-2 inhibitors superior to traditional non- steroidal anti-inflammatory drugs? BMJ. 324:2002;1287-1288
39. Pharmacia, Pfizer. Celecoxib prescribing information.http://www.celebrex. com/pdf/Celebrex_PI.pdf (accessed May 18, 2004).
40. Novartis Pharmaceuticals. Prescribing information: Voltaren (diclofenac sodium enteric-coated tablets), February, 2003.http://www.pharma.us.novartis. com/product/pi.jsp (accessed May 18, 2004).
41. IMS Health. IMS MIDAS prescribing insights (measure: prescriptions, period covered: 2001-2003).http://www.ims-global.com/insight/insight.htm (accessed July 29, 2004).
42. IMS Health. IMS MIDAS quantum (measure: units, period covered: 2001-2003).http://www.ims-global.com/insight/insight.htm (accessed July 29, 2004).
43. US Food and Drug Administration. FDA spontaneous reports: hepatic adverse event reporting rates for NSAIDs and coxibs using the FDA Spontaneous Reports Adverse Event Reporting System from 1969 to June 2003.http://www.fda.gov/cder/ aers/default.htm (accessed Aug 4, 2004)
44. Gillen D, McColl KE. Problems associated with the clinical use of proton pump inhibitors. Pharmacol Toxicol. 89:2001;281-286
45. Kuipers EJ, Lee A, Klinkenberg-Knol EC, Meuwissen SG. Review article: the development of atrophic gastritis - Helicobacter pylori and the effects of acid suppressive therapy. Aliment Pharmacol Ther. 9:1995;331-340
46. Hawkey CJ, Naesdal J, Wilson I, et al. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut. 51:2002;336-343
47. Graham DY. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications - future research needs. Am J Med. 110:2001;58S-61S